FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1851059930> ?p ?o ?g. }

• W1851059930 endingPage "95" @default.
• W1851059930 startingPage "95" @default.
• W1851059930 abstract "The Diabetic Retinopathy Clinical Research Network (DRCR Network), sponsored by the National Eye Institute, reported the results of a comparative effectiveness randomized clinical trial (RCT) evaluating the 3 anti-vascular endothelial growth factor (anti-VEGF) agents aflibercept (2.0 mg), bevacizumab (1.25 mg), and ranibizumab (0.3 mg) for treatment of diabetic macular edema (DME) involving the center of the retina and associated with visual acuity loss. The many important findings of the RCT prompted the American Society of Retina Specialists to convene a group of experts to provide their perspective regarding clinically relevant findings of the study.To describe specific outcomes of the RCT judged worthy of highlighting, to discuss how these and other clinically relevant results should be considered by specialists treating DME, and to identify unanswered questions that merit consideration before treatment.The DRCR Network-authored publication on primary outcomes of the comparative effectiveness RCT at 89 sites in the United States. The study period of the RCT was August 22, 2012, to August 28, 2013.On average, all 3 anti-VEGF agents led to improved visual acuity in eyes with DME involving the center of the retina and with visual acuity impairment, including mean (SD) improvements by +13.3 (11.1) letters with aflibercept vs +9.7 (10.1) letters with bevacizumab (P < .001) and +11.2 (9.4) letters with ranibizumab (P = .03). Worse visual acuity when initiating therapy was associated with greater visual acuity benefit of aflibercept (+18.9 [11.5]) over bevacizumab (+11.8 [12.0]) or ranibizumab (14.2 [10.6]) 1 year later (P < .001 for interaction with visual acuity as a continuous variable, and P = .002 for interaction with visual acuity as a categorical variable). It is unknown whether different visual acuity outcomes associated with the use of the 3 anti-VEGF agents would be noted with other treatment regimens or with adequately repackaged bevacizumab, as well as in patients with criteria that excluded them from the RCT, such as persistent DME despite recent anti-VEGF treatment.On average, all 3 anti-VEGF agents led to improved visual acuity in eyes with DME involving the center of the retina and visual acuity impairment. Worse visual acuity when initiating therapy was associated with greater visual acuity benefit of aflibercept over bevacizumab or ranibizumab 1 year later. Care needs to be taken when attempting to extrapolate outcomes of this RCT to differing treatment regimens. With access to adequately repackaged bevacizumab, many specialists might initiate therapy with bevacizumab when visual acuity is good (ie, 20/32 to 20/40 as measured in the DRCR Network), recognizing that the cost-effectiveness of bevacizumab outweighs that of aflibercept or ranibizumab." @default.
• W1851059930 created "2016-06-24" @default.
• W1851059930 creator A5006761392 @default.
• W1851059930 creator A5018888370 @default.
• W1851059930 creator A5019296720 @default.
• W1851059930 creator A5020800294 @default.
• W1851059930 creator A5026181496 @default.
• W1851059930 creator A5028848967 @default.
• W1851059930 creator A5029329549 @default.
• W1851059930 creator A5030449236 @default.
• W1851059930 creator A5039879095 @default.
• W1851059930 creator A5051846193 @default.
• W1851059930 creator A5054503683 @default.
• W1851059930 creator A5058044536 @default.
• W1851059930 creator A5059376308 @default.
• W1851059930 creator A5087700840 @default.
• W1851059930 creator A5090646410 @default.
• W1851059930 creator A5091046540 @default.
• W1851059930 date "2016-01-01" @default.
• W1851059930 modified "2023-10-04" @default.
• W1851059930 title "Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema" @default.
• W1851059930 cites W1786299986 @default.
• W1851059930 cites W1792426984 @default.
• W1851059930 cites W1973545783 @default.
• W1851059930 cites W2022886290 @default.
• W1851059930 cites W2330800912 @default.
• W1851059930 cites W2492141817 @default.
• W1851059930 cites W2616361514 @default.
• W1851059930 doi "https://doi.org/10.1001/jamaophthalmol.2015.4110" @default.
• W1851059930 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26512939" @default.
• W1851059930 hasPublicationYear "2016" @default.
• W1851059930 type Work @default.
• W1851059930 sameAs 1851059930 @default.
• W1851059930 citedByCount "78" @default.
• W1851059930 countsByYear W18510599302016 @default.
• W1851059930 countsByYear W18510599302017 @default.
• W1851059930 countsByYear W18510599302018 @default.
• W1851059930 countsByYear W18510599302019 @default.
• W1851059930 countsByYear W18510599302020 @default.
• W1851059930 countsByYear W18510599302021 @default.
• W1851059930 countsByYear W18510599302022 @default.
• W1851059930 countsByYear W18510599302023 @default.
• W1851059930 crossrefType "journal-article" @default.
• W1851059930 hasAuthorship W1851059930A5006761392 @default.
• W1851059930 hasAuthorship W1851059930A5018888370 @default.
• W1851059930 hasAuthorship W1851059930A5019296720 @default.
• W1851059930 hasAuthorship W1851059930A5020800294 @default.
• W1851059930 hasAuthorship W1851059930A5026181496 @default.
• W1851059930 hasAuthorship W1851059930A5028848967 @default.
• W1851059930 hasAuthorship W1851059930A5029329549 @default.
• W1851059930 hasAuthorship W1851059930A5030449236 @default.
• W1851059930 hasAuthorship W1851059930A5039879095 @default.
• W1851059930 hasAuthorship W1851059930A5051846193 @default.
• W1851059930 hasAuthorship W1851059930A5054503683 @default.
• W1851059930 hasAuthorship W1851059930A5058044536 @default.
• W1851059930 hasAuthorship W1851059930A5059376308 @default.
• W1851059930 hasAuthorship W1851059930A5087700840 @default.
• W1851059930 hasAuthorship W1851059930A5090646410 @default.
• W1851059930 hasAuthorship W1851059930A5091046540 @default.
• W1851059930 hasConcept C118487528 @default.
• W1851059930 hasConcept C134018914 @default.
• W1851059930 hasConcept C141071460 @default.
• W1851059930 hasConcept C168563851 @default.
• W1851059930 hasConcept C2776403814 @default.
• W1851059930 hasConcept C2776694085 @default.
• W1851059930 hasConcept C2777802072 @default.
• W1851059930 hasConcept C2778257484 @default.
• W1851059930 hasConcept C2778749236 @default.
• W1851059930 hasConcept C2779829184 @default.
• W1851059930 hasConcept C2781100027 @default.
• W1851059930 hasConcept C555293320 @default.
• W1851059930 hasConcept C71924100 @default.
• W1851059930 hasConceptScore W1851059930C118487528 @default.
• W1851059930 hasConceptScore W1851059930C134018914 @default.
• W1851059930 hasConceptScore W1851059930C141071460 @default.
• W1851059930 hasConceptScore W1851059930C168563851 @default.
• W1851059930 hasConceptScore W1851059930C2776403814 @default.
• W1851059930 hasConceptScore W1851059930C2776694085 @default.
• W1851059930 hasConceptScore W1851059930C2777802072 @default.
• W1851059930 hasConceptScore W1851059930C2778257484 @default.
• W1851059930 hasConceptScore W1851059930C2778749236 @default.
• W1851059930 hasConceptScore W1851059930C2779829184 @default.
• W1851059930 hasConceptScore W1851059930C2781100027 @default.
• W1851059930 hasConceptScore W1851059930C555293320 @default.
• W1851059930 hasConceptScore W1851059930C71924100 @default.
• W1851059930 hasIssue "1" @default.
• W1851059930 hasLocation W18510599301 @default.
• W1851059930 hasLocation W18510599302 @default.
• W1851059930 hasOpenAccess W1851059930 @default.
• W1851059930 hasPrimaryLocation W18510599301 @default.
• W1851059930 hasRelatedWork W2084462826 @default.
• W1851059930 hasRelatedWork W2331198753 @default.
• W1851059930 hasRelatedWork W2551646801 @default.
• W1851059930 hasRelatedWork W2553987180 @default.
• W1851059930 hasRelatedWork W2559118752 @default.
• W1851059930 hasRelatedWork W2618382267 @default.
• W1851059930 hasRelatedWork W2790038519 @default.
• W1851059930 hasRelatedWork W2885663288 @default.

• next